Altimmune Reveals Promising Data from Recent Clinical Trials
Recently, Altimmune, Inc. (Nasdaq: ALT), a pioneering biopharmaceutical company focusing on innovative peptide-based therapies for liver and cardiometabolic issues, published exciting findings from its ongoing IMPACT Phase 2b trial in The Lancet. This publication shares 24-week results that highlight both the efficacy and safety of pemvidutide in treating metabolic dysfunction-associated steatohepatitis (MASH).
Significant Findings in MASH Treatment
The trial results demonstrate noteworthy advancements, including substantial resolutions of MASH, marked weight loss, and a favorable side effect profile for patients. As a dual glucagon/GLP-1 agonist, pemvidutide targets both the metabolic and hepatic aspects of this complex condition.
IMPACT Phase 2b Trial Overview
This randomized, double-blind trial enrolled 212 participants diagnosed with biopsy-confirmed MASH. Two specific dosage regimens were evaluated: 1.2 mg and 1.8 mg of pemvidutide, compared to a placebo over a 24-week period. The primary efficacy endpoints focused on MASH resolution without worsening fibrosis, which was significantly achieved in participants receiving pemvidutide.
Clinical Impact of Pemvidutide
Dr. Mazen Noureddin, the trial's principal investigator, expressed great enthusiasm regarding the findings. He emphasized that reversing liver fibrosis is paramount for preventing severe health risks such as cirrhosis. The observed improvements after just 24 weeks reveal the potential impact of pemvidutide on long-term health outcomes for MASH patients.
Results and Key Indicators
Among the critical outcomes were impressive reductions in liver fat and inflammation. The data reflected strong evidence of improved liver function markers, including various non-invasive tests. For instance, the results revealed:
- MASH resolution rates of 58% for the 1.2 mg group and 52% for the 1.8 mg group, compared to 20% in the placebo group.
- A decrease in body weight by an average of 4.8% in the 1.2 mg group and 5.8% in the 1.8 mg group, showcasing the medication's role in weight management.
- A remarkable normalization of liver fat content by 31% and 44% respectively in the treatment groups.
Safety Profile of Pemvidutide
Notably, the safety results were encouraging, with very few serious adverse events reported during the trial. This is crucial, especially when considering patient compliance and treatment sustainability. The dual mechanism of action inherent to pemvidutide might be significant in addressing both the metabolic and fibrotic components of liver disease.
Next Steps for Altimmune
With the substantial success reflected in the present study, Altimmune is excited about the future potential of pemvidutide. The company plans to present these findings in a late-breaking session at The Liver Meeting® 2025, furthering awareness and discussion around MASH treatments.
Future Trials and Developments
Altimmune is not stopping here. The company anticipates additional findings related to longer-term outcomes from the IMPACT trial to be shared in the upcoming quarters. With ongoing trials in alcohol use disorder and other related diseases, Altimmune aims to create a robust portfolio of therapeutic options.
About Altimmune
As a late clinical-stage biopharmaceutical company, Altimmune emphasizes its commitment to developing novel treatments for liver diseases and related metabolic disorders. Their lead candidate, pemvidutide, represents a thoughtful approach to addressing MASH and highlights the innovative spirit driving the company’s mission.
Frequently Asked Questions
What does pemvidutide treat?
Pemvidutide is being developed for treating metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD).
What were the main findings of the IMPACT Phase 2b trial?
The trial showed significant improvement in MASH resolution, weight loss, and reductions in liver fat and inflammation following pemvidutide treatment.
What is the safety profile of pemvidutide?
The safety analysis indicated few serious adverse events, suggesting good tolerability among participants using pemvidutide in clinical settings.
When will more results from the IMPACT trial be shared?
Additional findings, including longer-term outcomes, are expected to be reported in the near future, with discussions ongoing through 2025.
How can I learn more about Altimmune's developments?
For the latest updates on Altimmune and its product developments, you can visit their official website.
